[ARNI，心力衰竭新型治疗药物类别的新缩写]
[ARNI, new abbreviation for a new class of treatment of heart failure].
作者信息
Karimzadeh Soran, Mustafić Hazrije, Stampfli Andres Tomoe
机构信息
Service de cardiologie non invasive, Hôpital de La Tour, 1217 Meyrin.
出版信息
Rev Med Suisse. 2017 Mar 1;13(552):496-499.
ARNI (Angiontensin Receptor Neprilysin Inhibitor) are a new class of drug : the angiotensin and neprilysin inhibitors. This combined effect allows an optimisation of the heart failure treatment by acting on both pathways of the renin-angiotensin-aldosterone and of the natriuretic peptides. LCZ696 is a combined molecule of valsartan and sacubitril and is currently the only one on the market. Its efficacy has been shown in a large randomised trial in 2014, and LCZ696 is now part of the last 2016 European Society of Cardiology guidelines for the management of heart failure.
ARNI（血管紧张素受体脑啡肽酶抑制剂）是一类新型药物：血管紧张素和脑啡肽酶抑制剂。这种联合作用通过作用于肾素 - 血管紧张素 - 醛固酮和利钠肽两条途径，实现了心力衰竭治疗的优化。LCZ696是缬沙坦和沙库巴曲的复方制剂，是目前市场上唯一的此类药物。其疗效在2014年的一项大型随机试验中得到证实，LCZ696现已成为2016年欧洲心脏病学会最新心力衰竭管理指南的一部分。
Zotero 插件